Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

RxMx

We’re a healthcare company with exceptional technology solutions and longstanding industry experience. Founded by doctors, we’ve built our business on the idea that by automating certain tasks, we can empower HCPs to safely administer specialty medicines without increasing their burden, so they can focus on patients who need their care.

This is a FREE LISTING on PMHUB

Below are full profiles from other companies in related areas

- PMLiVE

Genetic Digital

We guide healthcare and life sciences organisations through digital transformation. Simplifying the complex world of tech and marketing, we create impactful assets and strategies to drive long-term growth and positive…

View Profile

Creative and design, Digital communications, IT solutions, Marketing consultancies, Medical communications

- PMLiVE

Nmblr

From day-one concept to launch and beyond, Nmblr is the strategy and collaboration platform that partners with biopharma teams.

View Profile

IT solutions

Company Details

RxMx
800 Third Avenue, Suite 2800, New York, New York, 10022, United States
(844) 311 3080
Contact RxMx
Website

 Latest Content from PMHub 

Embracing the demands of the empowered ‘consumer-savvy’ patient by Ann Generlich

White Papers and Resources | August 3, 2017 | Say Communications

Our access to information, which is now constantly at our fingertips and the explosion of new technologies has shifted the buying power to increasingly ‘consumer-savvy’ patients. These are patients who choose...

The Art of Agile Marketing

White Papers and Resources | August 3, 2017 | Anthill Agency

The industry knows that it needs become more responsive to its stakeholders. An agile approach – which quickly improves results through a process of rapid market feedback and response –...

Could ketamine be the next big thing in depression?

White Papers and Resources | August 3, 2017 | Blue Latitude Health

Account Executive Will Frostick discusses the established treatment model for depression and its limitations, as well as a new entrant poised to revolutionise the field – ketamine.

Attracting doctors to low-demand specialties: A role for industry?

White Papers and Resources | August 3, 2017 | Porterhouse Medical Group

 One of the major problems that healthcare systems around the world face is a paucity of medically qualified staff entering particular specialties and subspecialties. This can be due to a...

Men vs Women in emerging markets

White Papers and Resources | August 2, 2017 | Inizio

Our latest interactive infographic compares male vs female health characteristics in the BRIC emerging marketS

South Korea: The next global player?

White Papers and Resources | August 2, 2017 | Inizio

In this paper, we will explore some of the key trends and outlooks for South Korea in more detail, including what lies behind its presence at the extremes of two...

20 questions: Round 4

White Papers and Resources | August 2, 2017 | Inizio

As it's our 20th year anniversary, we invited our employees to play our version of 20 questions - this month "What’s been the funniest thing to happen to you whilst you’ve...

Will gene therapies finally be commercially viable to pharma?

White Papers and Resources | August 2, 2017 | Inizio

Our latest Free Thinking white paper explores the science behind the idea of gene therapy and takes a look at some of the core challenges medical researchers have faced when...

Wargaming in HCV

White Papers and Resources | August 2, 2017 | Inizio

The challenge:Our client had a product ready for launch in the HCV landscape. A number of new competitor products were expected to alter the market dynamics. Given the stage of...

Living with Lupus: Breaking the Silence

White Papers and Resources | August 2, 2017 | Inizio

Published in eyeforpharma July 2017 by Mariel Metcalfe